A research team from Vanderbilt University, University of North Carolina, and Gilead Sciences has just released new findings in Science Translational Medicine that a new antiviral drug candidate inhibits a broad range of coronaviruses, including SARS and MERS.

Previous articleAvoiding CRISPR-Mediated Gene-Drive–Evolved Resistance in Mosquitoes
Next articleHeptares, PeptiDream Partner on GPCR-Targeting Drugs for Inflammatory Diseases